



Clinical Policy: Zolbetuximab-clzb (Vyloy)

Reference Number: LA.PHAR.705

Effective Date: 09.17.25

Last Review Date: ~~05.08.25~~03.30.26

Line of Business: Medicaid

[Coding Implications](#)
[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Formatted: Strong, Font: Arial Unicode MS, Not Bold, Underline, Font color: Auto

****Please note: This policy is for medical benefit****

Description

Zolbetuximab-clzb (Vyloy[®]) is a claudin (CLDN) 18.2-directed cytolytic antibody.

FDA Approved Indication(s)

Vyloy is indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are CLDN 18.2 positive as determined by an FDA-approved test.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Louisiana Healthcare Connections that Vyloy is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Gastric or Gastroesophageal Junction Adenocarcinoma (must meet all):

1. Diagnosis of gastric or gastroesophageal junction adenocarcinoma;
2. Prescribed by or in consultation with an oncologist;
3. Age \geq 18 years;
4. One of the following (a or b):
 - ~~4.a.~~ Disease is locally advanced unresectable, recurrent, or metastatic;
 - b. Member is not a surgical candidate, and request is for palliative therapy;
5. Disease is HER2-negative;
6. Tumor is CLDN 18.2 positive;
7. Request is for first-line treatment;
8. Vyloy is prescribed in combination with both of the following (a and b):
 - a. Fluoropyrimidine (e.g., capecitabine, fluorouracil)-containing chemotherapy;
 - b. Platinum (e.g., oxaliplatin)-containing chemotherapy;
9. Request meets one of the following (a or b):*
 - a. Dose does not exceed an initial 800 mg/m² dose followed by either 600 mg/m² every 3 weeks or 400 mg/m² every 2 weeks;

Formatted: Indent: Left: 0.75"

- b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 6-12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53.

II. Continued Therapy.

A. Gastric or Gastroesophageal Junction Adenocarcinoma (must meet all):

1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Vyloy for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose does not exceed 600 mg/m² every 3 weeks or 400 mg/m² every 2 weeks;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – LA.PMN.53.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CLDN: claudin

FDA: Food and Drug Administration

HER2: human epidermal growth factor receptor 2

Appendix B: Therapeutic Alternatives

CLINICAL POLICY
Zolbetuximab-clzb



Not applicable

Appendix C: Contraindications/Boxed Warnings
None reported

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Gastric or gastroesophageal junction adenocarcinoma	First dose: 800 mg/m ² IV Subsequent doses: <ul style="list-style-type: none">• 600 mg/m² IV every 3 weeks, or• 400 mg/m² IV every 2 weeks	See dosing regimen

VI. Product Availability

Lyophilized powder in single-dose vials: 100 mg, 300 mg

VII. References

1. Vyloy Prescribing Information. Northbrook, IL: Astellas Pharma US, Inc.; ~~October 2024~~ June 2025. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf.vyloy.com. Accessed ~~October 29, 2024~~ July 14, 2025.
2. Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023 May 20; 401(10389): 1655-1668.
3. Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023 Aug; 29(8): 2133-2141.
4. National Comprehensive Cancer Network. ~~Esophageal Drugs and Esophagogastric Junction Cancers Version 4.2024~~ Biologics Compendium. Available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf.drug_compendium. Accessed ~~October 29, 2024~~ July 15, 2025.
5. National Comprehensive Cancer Network. Esophageal and Esophagogastric Junction Cancers Version 3.2025. Available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed July 15, 2025.
- 5-6. National Comprehensive Cancer Network. Gastric Cancer Version ~~4.2024~~ 2.2025. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed ~~October 29, 2024~~ July 15, 2025.

Formatted: Font color: Auto

Formatted: Don't keep with next, Don't keep lines together

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CLINICAL POLICY
Zolbetuximab-clzb



HCPSC Codes	Description
C9303 J1326	Injection, zolbetuximab-clzb, <u>42</u> mg

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Converted Corporate to LHCC policy	05.08.25	<u>08.14.25</u>
<u>Annual review: added options for use in recurrent disease and as palliative therapy in members who are not surgical candidates per NCCN; extended initial approval duration from 6 to 12 months; HCPSC code added [J1326] replacing code [C9303]; references reviewed and updated.</u>	<u>03.30.26</u>	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Louisiana Healthcare Connections administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to

CLINICAL POLICY
Zolbetuximab-clzb



recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©~~2025~~-2026 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.